Zogenix, Inc. (NASDAQ: ZGNX) is a biopharmaceutical company dedicated to developing and commercializing transformative therapies for rare diseases, with a particular focus on severe pediatric epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome (LGS). The company's lead investigational product, ZX008 (low dose fenfluramine), is designed to treat these complex and severe forms of epilepsy. Zogenix serves patients, healthcare professionals, and their families by providing innovative treatments that aim to significantly improve quality of life.

Operating in the biopharmaceutical market, Zogenix's business model revolves around the research, development, and commercialization of its therapeutic candidates. The company generates revenue through the sale of its approved therapies and potentially through partnerships and licensing agreements. Zogenix is committed to transparency and high standards, employing exceptional individuals who are passionate about creating value for patients, healthcare providers, employees, and shareholders.

Keywords: biopharmaceutical, rare diseases, pediatric epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, ZX008, fenfluramine, transformative therapies, patient-focused, innovation.